

## Navana Pharmaceuticals PLC.

House # 99, Road # 04, Block-B, Banani, Dhaka-1213, Bangladesh.

Tel: +880-2-550 33580-3, Fax: +880-2-550 33579

E-mail: admin@navanapharma.com

## **Dividend Compliance Report (2023-2024)**

	Dividend Distribution Comp		
	Under Clause (6) of the Directive No. BSEC/CMRRO	CD/2021-386/03,dated:14/01/2021	
1	Name of the Issuer/Securities/Mutual Fund	Navana Pharmaceuticals PLC.	
2	Particulars of Issuer DP	649	
3	Type of the Dividend (Annual/ Interim) (Put tick mark (a) on the recommended option)	a) Annual 🗸 b) Interim	
4	Whether audited or not for Interim Dividend (Put tick mark (a) on the recommended option)	a) Audited v b) Unaudited	
5	Date of recommendation of Dividend by the Board of Directors/Trustee(Enclose Copy of PSI)	28.10.2024	
6	Whether Dividend recommended other than directors or sponsors or any other classes (Put tick mark (a) on the recommended option)	a) Yes 🕠 b) No	
7	Record date for entitlement	19.11.2024	
8	Rate of Dividend recommendation by the Board of Directors/Trustee	a) Cash Dividend: 14% only for general shareholders     b) Bonus/Stock Dividend:	
9	Dividend recommended-Type (Put tick mark (a) on the recommended option)	a) Cash v b) Stock	
10	Securities/mutual fund traded under which categories (Put tick mark (a) on the recommended option)	a) A v b) B c) G d) N e) Z	
11	Date of transfer to a separate bank account (pls. mention bank details) or provisional credit of shares/units by CDBL	A) Date of Cash Dividend Transfer: 21.01.2025, Bank: <b>Meghna Bank PLC.</b> , A/C No. <b>110113500000190</b> , Branch: <b>Principal</b>	
12	Date of approval of Dividend at AGM	31.12.2024	
13	Rate of Dividend approved at AGM-details at Annexure, (in any change)	a) Cash Dividend: 14% only for general shareholders	
14	Date of commencement of disbursement of Cash and Stock dividend	Disbursed to the respective Bank Accounts of the Shareholders' (who are registered as on Record Date i.e. 19.11.2024) linked with their recorded BO number through BEFTN, EFT & Dividend Warrant from 21.01.2025 to 29.01.2025. The remaining un-remitted cash dividends, due to non-availability of BEFTN facilities or error in information have been dispatched by courier services to the respective shareholders' address registered with the Company on 29.01.2025	





## Navana Pharmaceuticals PLC.

House # 99, Road # 04, Block-B, Banani, Dhaka-1213, Bangladesh.

Tel: +880-2-550 33580-3, Fax: +880-2-550 33579

E-mail: admin@navanapharma.com

		a) PETTN	D) D	
		a) BEFTN <sub>√</sub>	B) Bank Transf	er 🗸
15	Mode of disbursement of cash dividend			
	(Put tick mark (a) on the recommended option)	C) MFC d)	Dividend warran	+ 🗔
		,		<b>.</b>
		e) Any other mod	de √	
	Date of completion of disbursement of cash Dividend and Stock	A) Data of Co	-L D: : L -	
16	Dividend [Enclose Bank statements and Corporate Action	A) Date of Ca	sh Dividend Trans 25 to 29.01.2025	rer:
	processing Report (DP70)]	B) Date of Cre	edit of Shares/unit	c by CDBL . N/A
17	Paid-up-capital of the issuer-before corporate	b) bate of cire	edit of Shares/unit	S DY CDBL: N/A
	action/entitlement		N/A	1
18	Numbers of securities/shares outstanding-before corporate actio	n/entitlement:	N/A	
			end <b>TK. 47,451</b> ,	013.40
19	Total cash in taka or stock (nos. shares) dividend as per	(Included	Tax TK. 6,842,8	44.05)
	corporate declaration		ck Dividend: N/P	,,,,,
20	Distribution/disbursement details of Cash & Stock	Cash-Net	,	
	Dividend:	Dividend (Tk.)	Stock (nos.)	Annexures
	A. Mode of Dividend Payment/credit for the concerned year:			
	a) through BEFTN or directly credited to respective BO	31,504,454.03		Bank
	B) through Bank Transfer other than entitled BO-Margin Loan			Statement
=	C) through Bank Transfer	F7.06		Bank
		57.96		Statement
	d) through Mobile Financial Service (MFS)			
	e) through any other mode as approved by Bangladesh Bank			
	f) through transfer to Suspense Account for dematerialized Shares (BO wise detailed with reason should be maintained			
	and submitted)			
	g) through issuance of Dividend warrant/ Cheque or			
	issue of Shares to Suspense Account for Non-dematerialized	2 005 402 76		Bank
	securities	3,905,493.76		Statement
21	Total Dividend maid (and the 15 miles			Pont
	Total Dividend paid/credited for the concerned year	35,410,005.75		Bank Statement
22	Total unpaid/undistributed Dividend/accrued during the period	5,937,064.6		Statement
23	Total unpaid/undistributed Dividend/accrued as on 1st day of		,	
	Accounting year (as per Audited Accounts) as on 01.07.2024	7,335,212.4	N/P	
24	Transfer to suspense Account for Demate Shares or any other	N/P	N/P	
-	reasons during concerned year	14/ F	IN/P	
	A. Mode of Dividend Receipts/payment/credit for the previous years:			
	a)through BEFTN directly credited to respective BO		N/P	
	b)through Bank Transfer	31,277,153.31	N/P	
	C) through Mobile Financial Service (MFS)	1,313,938.05	N/P	
	d) through any other mode as approved by Bangladesh Bank	N/P	N/P	
	(Dividend warrant/Cheque)	92 1/1 751 04	NI /S	
	e)through transfer to/from Suspense Account for Demate	83,141,751.94	N/P	
	Shares or any other reasons			
	f)through issuance of Dividend Warrant or issue of shares to			
	Suspense Account for non-dematerialized	N/P	N/P	
	securities/shares/units		11/1	





## Navana Pharmaceuticals PLC.

House # 99, Road # 04, Block-B, Banani, Dhaka-1213, Bangladesh.

Tel: +880-2-550 33580-3, Fax: +880-2-550 33579

E-mail: admin@navanapharma.com

		=a aariii laraarapiiai iia.
directed by commission after 3 years or forfeit of share to Suspense Account for non-dematerialized securities	N/P	N/P
Total Dividend paid/credited for previous years as on 30.01.2025:	25,755.57	N/P
Total unpaid/undistributed Dividend for previous years (23+24-25) Taka/Nos	7,309,456.83	N/P
Grand Total of unpaid/undistributed Dividend (22+26)		N/P
Aging of grand Total of unpaid/undistributed Dividend		N/P
		N/P
More than 4 years; balance		N/P
More than 5 years & above ; balance		N/P
Total of unpaid/undistributed Dividend for previous years		N/P
(Supporting bank statement and balances of securities with the Depository)	N/P	N/P
	Suspense Account for non-dematerialized securities  Total Dividend paid/credited for previous years as on 30.01.2025:  Total unpaid/undistributed Dividend for previous years (23+24-25) Taka/Nos  Grand Total of unpaid/undistributed Dividend (22+26)  Aging of grand Total of unpaid/undistributed Dividend for previous years:  More than 3 years; balance  More than 4 years; balance  More than 5 years & above; balance  Total of unpaid/undistributed Dividend for previous years  (Supporting bank statement and balances of securities	directed by commission after 3 years or forfeit of share to Suspense Account for non-dematerialized securities  Total Dividend paid/credited for previous years as on 30.01.2025:  Total unpaid/undistributed Dividend for previous years (23+24-25) Taka/Nos  Grand Total of unpaid/undistributed Dividend (22+26)  Aging of grand Total of unpaid/undistributed Dividend for previous years:  More than 3 years; balance  More than 4 years; balance  More than 5 years & above; balance  Total of unpaid/undistributed Dividend for previous years  (Supporting bank statement and balances of securities

With reasons and submit along with bank statements and other supporting documents. The issuer shall fill up all the

Reporting Date: February 05, 2025

Accounts

applicable fields.

Authorize Signature with seal (With name & designation)

Lorens Shamol Mollick FCS Company Secretary Navana Pharmaceuticals PLC.